MedTrace Logo

Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer

NCT01654367 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2012-07-31

No results posted yet for this study

Summary

Select patients of primary breast cancer whose hormone receptor is positive and accepted postoperative adjuvant aromatase inhibitors for endocrine treatment.Treat them with zoledronic acid 4mg intravenous infusion every six months until the end of the aromatase treatment. Assess the disease-free survival; overall survival; combination of security, as well as the situation of bone loss.

Conditions

Interventions

DRUG

Zoledronic Acid and Aromatase Inhibitors

Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy

Sponsors & Collaborators

  • Tianjin Medical University

    lead OTHER

Principal Investigators

  • Jin Zhang, Professor · Tianjin Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-12-31
Completion
2013-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01654367 on ClinicalTrials.gov